Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed and gemcitabine scheduling pilot study in advanced non-small cell lung cancer
2006-001836-32Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and gemcitabine in non-small cell lung cancer (NSCLC) and thoracic cancer, sponsored by Eli Lilly and Company. Primary endpoints: Best timing of pemetrexed-gemcitabine administration and dCK and hENT induction by pemetrexed. Started Mar 2007; status: completed.
02
Drugs
pemetrexedgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)thoracic cancer
Beyond the preview
Go deeper on 2006-001836-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001836-32.